Payment overview · 2025
General Payments
$1,481.23
87 reported records · 19 companies
Healthcare provider profile · identity verified
Benjamin Paul Williams, MD
Allopathic & Osteopathic Physicians|Internal Medicine · THOMASTON, GA · NPI 1508880352
Verified facts
What the public records show
CMS Open Payments records show Benjamin Paul Williams, MD received $1,481.23 in general payments during 2025 across 87 reported records.
PFIZER INC. accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 434 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $311.48 | 21.0% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $280.71 | 18.9% | 22 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $201.11 | 13.6% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $138.16 | 9.3% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $81.17 | 5.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $68.07 | 4.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.39 | 3.9% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.53 | 3.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $47.14 | 3.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $38.75 | 2.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $32.39 | 2.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $25.19 | 1.7% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.74 | 1.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.86 | 1.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.69 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.31 | 1.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.07 | 1.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.56 | 1.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $13.91 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,481.23 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $253.28 | 20 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $237.23 | 19 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $151.58 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $139.24 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $113.41 | 10 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $111.42 | 7 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $111.42 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $111.42 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $87.12 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $86.08 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $68.07 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $65.50 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $58.39 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $58.39 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $52.41 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.12 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $47.53 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $47.14 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.00 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.00 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.17 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $38.75 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $32.39 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.43 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $25.19 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| PULMICORT Normalized: pulmicort |
Drug | AstraZeneca Pharmaceuticals LP | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 434 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 136 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 126 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 204 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
136 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
19 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
126 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
204 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
434 | 63 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 30 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 887 | 167 |
| Omeprazole | Omeprazole | 864 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 846 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 773 | 152 |
| Escitalopram Oxalate | Escitalopram Oxalate | 682 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 661 | 102 |
| Losartan Potassium | Losartan Potassium | 643 | 146 |
| Atorvastatin Calcium | Atorvastatin Calcium | 620 | 121 |
| Tramadol Hcl | Tramadol Hcl | 607 | 116 |
| Alprazolam | Alprazolam | 604 | 89 |
| Clopidogrel | Clopidogrel Bisulfate | 521 | 97 |
| Metoprolol Tartrate | Metoprolol Tartrate | 501 | 81 |
| Lisinopril | Lisinopril | 485 | 113 |
| Furosemide | Furosemide | 462 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 449 | 104 |
| Trazodone Hcl | Trazodone Hcl | 441 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 439 | 83 |
| Eliquis | Apixaban | 434 | 63 |
| Simvastatin | Simvastatin | 371 | 100 |
| Metformin Hcl | Metformin Hcl | 363 | 78 |
| Memantine Hcl | Memantine Hcl | 358 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 339 | 68 |
| Donepezil Hcl | Donepezil Hcl | 338 | 29 |
| Temazepam | Temazepam | 325 | 62 |
| Famotidine | Famotidine | 310 | 50 |
| Glipizide | Glipizide | 305 | 62 |
| Lorazepam | Lorazepam | 303 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 58 |
| Sertraline Hcl | Sertraline Hcl | 294 | 39 |
| Dexamethasone | Dexamethasone | 278 | 155 |
| Tizanidine Hcl | Tizanidine Hcl | 276 | 58 |
| Carvedilol | Carvedilol | 265 | 63 |
| Potassium Chloride | Potassium Chloride | 260 | 48 |
| Clonazepam | Clonazepam | 258 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 58 |
| Meloxicam | Meloxicam | 237 | 61 |
| Sucralfate | Sucralfate | 225 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 211 | 36 |
| Ozempic | Semaglutide | 204 | 36 |
| Glimepiride | Glimepiride | 203 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 197 | 49 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 197 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 176 | 43 |
| Spironolactone | Spironolactone | 167 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 165 | 33 |
| Allopurinol | Allopurinol | 160 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 155 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 155 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 147 | 33 |
| Naproxen | Naproxen | 141 | 37 |
| Farxiga | Dapagliflozin Propanediol | 136 | 27 |
| Ondansetron Odt | Ondansetron | 134 | 50 |
| Ropinirole Hcl | Ropinirole Hcl | 134 | 18 |
| Meclizine Hcl | Meclizine Hcl | 132 | 33 |
| Metformin Hcl Er | Metformin Hcl | 130 | 33 |
| Montelukast Sodium | Montelukast Sodium | 130 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 16 |
| Jardiance | Empagliflozin | 126 | 22 |
| Cefuroxime | Cefuroxime Axetil | 125 | 93 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 122 | 94 |
| Torsemide | Torsemide | 121 | 36 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 117 | 14 |
| Methocarbamol | Methocarbamol | 114 | 30 |
| Estradiol | Estradiol | 111 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 20 |
| Fluconazole | Fluconazole | 109 | 47 |
| Pregabalin | Pregabalin | 109 | 23 |
| Bupropion Hcl | Bupropion Hcl | 105 | 21 |
| Atenolol | Atenolol | 96 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 96 | 12 |
| Xarelto | Rivaroxaban | 95 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 19 |
| Cephalexin | Cephalexin | 90 | 66 |
| Indapamide | Indapamide | 90 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 88 | 20 |
| Divalproex Sodium | Divalproex Sodium | 86 | suppressed |
| Myrbetriq | Mirabegron | 85 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 85 | 11 |
| Sotalol | Sotalol Hcl | 83 | 21 |
| Ranolazine Er | Ranolazine | 81 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 80 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 12 |
| Finasteride | Finasteride | 77 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 21 |
| Diazepam | Diazepam | 73 | 13 |
| Cefdinir | Cefdinir | 71 | 60 |
| Clonidine Hcl | Clonidine Hcl | 71 | suppressed |
| Fenofibrate | Fenofibrate | 70 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 70 | 18 |
| Januvia | Sitagliptin Phosphate | 68 | 11 |
| Linzess | Linaclotide | 68 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 67 | suppressed |
| Entresto | Sacubitril/Valsartan | 67 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 67 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 29 |
| Warfarin Sodium | Warfarin Sodium | 66 | 19 |
| Bumetanide | Bumetanide | 64 | 13 |
| Lamotrigine | Lamotrigine | 64 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 63 | 11 |
| Ezetimibe | Ezetimibe | 61 | 17 |
| Prednisone | Prednisone | 61 | 23 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Mirtazapine | Mirtazapine | 57 | 13 |
| Valsartan | Valsartan | 57 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 56 | suppressed |
| Brilinta | Ticagrelor | 54 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 11 |
| Demeclocycline Hcl | Demeclocycline Hcl | 53 | suppressed |
| Lubiprostone | Lubiprostone | 53 | suppressed |
| Ibuprofen | Ibuprofen | 52 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 52 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 49 | suppressed |
| Mupirocin | Mupirocin | 49 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | suppressed |
| Azithromycin | Azithromycin | 47 | 37 |
| Novolog Flexpen | Insulin Aspart | 47 | suppressed |
| Synthroid | Levothyroxine Sodium | 47 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 46 | 22 |
| Methylprednisolone | Methylprednisolone | 46 | 11 |
| Hydrocortisone | Hydrocortisone | 44 | 15 |
| Carisoprodol | Carisoprodol | 43 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 42 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 40 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 27 |
| Verapamil Er | Verapamil Hcl | 39 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 32 |
| Primidone | Primidone | 35 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Celecoxib | Celecoxib | 34 | 14 |
| Colesevelam Hcl | Colesevelam Hcl | 34 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 32 | suppressed |
| Levemir Flexpen | Insulin Detemir | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Procto-Med Hc | Hydrocortisone | 32 | 11 |
| Colchicine | Colchicine | 31 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 30 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 22 |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 14 |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 26 | 16 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 24 | suppressed |
| Nystatin | Nystatin | 24 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 15 |
| Baclofen | Baclofen | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 20 | 14 |
| Irbesartan | Irbesartan | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 13 |
| Tamoxifen Citrate | Tamoxifen Citrate | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Dofetilide | Dofetilide | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Niacin Er | Niacin | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 12 |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Propylthiouracil | Propylthiouracil | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Perphenazine | Perphenazine | 11 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,481.23 · 87 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, GEMTESA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PULMICORT, QULIPTA, Qelbree, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, VYNDAMAX, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error